The Structure Determination of Tegoprazan((S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-formamide) Polymorphs A and B by Laboratory X-Ray Powder Diffraction
Abstract
Tegoprazan is a potassium ion-competitive acid blocker (P-CAB) and novel inhibitor of gastric acid secretion. The crystal is available in two polymorphs, A and B, but their crystal structures have not yet been reported. Liquid and solid-state NMR were used to investigate the tautomeric state, which was found to be identical in both phases. Using these tautomers, the crystal structures of both polymorphs were determined from the X-ray diffraction data obtained with a laboratory powder X-ray diffractometer, employing simulated annealing and Rietveld refinement. It was found that both phases crystallized in the monoclinic space group P21, Z = 4, with the asymmetric unit containing two symmetrically independent molecules.
Read the paper
Related studies
- Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.